Status:
RECRUITING
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
Lead Sponsor:
Peking University First Hospital
Conditions:
Multiple Myeloma
Renal Injury
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Multiple myeloma (MM) is still an incurable hematological tumor, and renal involvement is the main factor of poor prognosis. The recovery of renal function can partially reverse its poor outcome. Alth...
Detailed Description
For patients with multiple myeloma with renal impairment, the same disease stage and the same treatment regimen have different therapeutic effects. In the era of new drugs, studies have shown that ear...
Eligibility Criteria
Inclusion
- Adults aged 18 years or older
- Confirmed diagnosis of symptomatic myeloma with renal impairment
- Confirmed myeloma-associated nephropathy (e.g. light chain cast nephropathy, AL amyloidosis, MIDD etc.) on renal biopsy
- Willingness and eligibility for autologous hematopoietic stem cell transplantation
Exclusion
- Pre-existing chronic kidney disease unrelated to myeloma, such as diabetic nephropathy or hypertensive nephropathy
- Plasma cell leukemia or extramedullary plasmacytoma
- Contraindications or prior severe allergic reactions to study medications
- Co-existing malignancy
- Co-existing medical conditions unsuitable for enrollment as determined by researchers, such as recent cardiovascular event, active infection etc.
Key Trial Info
Start Date :
January 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06203145
Start Date
January 2 2024
End Date
November 30 2025
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034